Metastatic prostate cancer: New insights and developments;Metastasiertes Prostatakarzinom: Neue Erkenntnisse und Entwicklungen

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 14, 2013, Pages 703-706

  Lorch, Anja ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

androgen deprivation therapy; castration resistant; chemotherapy; hormone therapy; prostate cancer

Indexed keywords

NOTE; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANDROSTADIENES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84875331354     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1332995     Document Type: Note

References (12)

1. de Bono J. S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet: 2010; 376 1147 1154
2. Fizazi K., Carducci M., Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistentprostate cancer: a randomised, double-blind study. Lancet: 2011; 377 813 822
3. Fizazi K., Scher H. I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol: 2012; 13 983 992
4. Hussain M., Tangen C. M., Higano C. et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol: 2012; 30 Suppl 01 Abstract 4
5. Kantoff P. W., Higano C. S., Shore N. D. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med: 2010; 363 411 422
6. Parker C., Heinrich D., O'Sullivan J. M. et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha- pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol: 2012; 30 Suppl. 05 Abstract 8
7. Logothetis C. J., Basch E., Molina A. et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol: 2012; 13 1210 1217
8. Mottet N., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol: 2011; 59 572 583
9. Petrylak D. P., Tangen C. M., Hussain M. H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med: 2004; 351 1513 1520 (Pubitemid 39315318)
10. Ryan C. J., Smith M. R., de Bono J. S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med: 2013; 368 138 148
11. Scher H. I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med: 2012; 367 1187 1197
12. Tannock I. F., de Wit R., Berry W. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med: 2004; 351 1502 1512 (Pubitemid 39315317)